Literature DB >> 10797527

Primary central nervous system lymphoma: a clinicopathological study of 28 cases.

H Pels1, M Deckert-Schlüter, A Glasmacher, R Kleinschmidt, R Oehring, H P Fischer, U Bode, U Schlegel.   

Abstract

A group of 28 consecutive patients (mean age 59 years) with primary central nervous system lymphoma (PCNSL) was treated with different regimens, including steroids only, radiotherapy (RT), chemotherapy or combinations of all. Lymphoma was classified as high grade malignant B-cell non-Hodgkin's lymphoma of the diffuse large cell type in each of these cases. RT alone led to tumour remission in more than 70 per cent, survival could be prolonged with additional chemotherapy. Thirteen patients were treated with chemotherapy alone; nine of them received a novel combined intraventricular and systemic polychemotherapy protocol based on high dose methotrexate (MTX) and high dose cytarabine (ara-C). The response rate was 90 per cent with 80 per cent complete responses. Neurotoxicity, i.e. white matter lesions associated with severe cognitive dysfunction affected both patients surviving RT more than a year and patients treated with combination RT/chemotherapy. Confluent white matter hyperintense lesions were detectable on MRI in three out of 13 patients treated with chemotherapy alone, however, cognitive dysfunction has not been detected in these patients. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797527     DOI: 10.1002/(sici)1099-1069(200003)18:1<21::aid-hon649>3.0.co;2-u

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

Review 1.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.

Authors:  H Pels; H Schulz; O Manzke; E Hom; A Thall; A Engert
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.